Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash from Financing Activities (2021 - 2025)

Verrica Pharmaceuticals has reported Cash from Financing Activities over the past 5 years, most recently at $13.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $13.6 million for Q4 2025, down 65.4% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (down 96.17% YoY), and the annual figure for FY2025 was $1.4 million, down 96.17%.
  • Cash from Financing Activities for Q4 2025 was $13.6 million at Verrica Pharmaceuticals, up from -$4.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for VRCA hit a ceiling of $44.0 million in Q3 2023 and a floor of -$16.9 million in Q3 2022.
  • Median Cash from Financing Activities over the past 5 years was -$18000.0 (2022), compared with a mean of $6.9 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 39288.37% in 2022 and later soared 168322.22% in 2023.
  • Verrica Pharmaceuticals' Cash from Financing Activities stood at -$3000.0 in 2021, then crashed by 561600.0% to -$16.9 million in 2022, then skyrocketed by 99.84% to -$27000.0 in 2023, then soared by 146122.22% to $39.4 million in 2024, then tumbled by 65.4% to $13.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were $13.6 million (Q4 2025), -$4.0 million (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.